- Home
- PYPD vs BUUU Comparison
PYPD vs BUUU Comparison
Compare PYPD & BUUU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PYPD
- BUUU
- Stock Information
- Founded
- PYPD 2008
- BUUU 2017
- Country
- PYPD Israel
- BUUU Hong Kong
- Employees
- PYPD N/A
- BUUU N/A
- Industry
- PYPD Medical/Dental Instruments
- BUUU Services-Misc. Amusement & Recreation
- Sector
- PYPD Health Care
- BUUU Consumer Discretionary
- Exchange
- PYPD Nasdaq
- BUUU Nasdaq
- Market Cap
- PYPD 60.4M
- BUUU 68.1M
- IPO Year
- PYPD 2020
- BUUU 2025
- Fundamental
- Price
- PYPD $3.63
- BUUU $8.18
- Analyst Decision
- PYPD Strong Buy
- BUUU
- Analyst Count
- PYPD 5
- BUUU 0
- Target Price
- PYPD $12.00
- BUUU N/A
- AVG Volume (30 Days)
- PYPD 87.2K
- BUUU 6.2K
- Earning Date
- PYPD 11-12-2025
- BUUU 11-19-2025
- Dividend Yield
- PYPD N/A
- BUUU N/A
- EPS Growth
- PYPD N/A
- BUUU N/A
- EPS
- PYPD N/A
- BUUU 0.05
- Revenue
- PYPD N/A
- BUUU $6,328,425.00
- Revenue This Year
- PYPD N/A
- BUUU N/A
- Revenue Next Year
- PYPD N/A
- BUUU N/A
- P/E Ratio
- PYPD N/A
- BUUU $124.78
- Revenue Growth
- PYPD N/A
- BUUU 8.88
- 52 Week Low
- PYPD $2.30
- BUUU $3.67
- 52 Week High
- PYPD $3.93
- BUUU $9.50
- Technical
- Relative Strength Index (RSI)
- PYPD 53.80
- BUUU N/A
- Support Level
- PYPD $3.59
- BUUU N/A
- Resistance Level
- PYPD $3.88
- BUUU N/A
- Average True Range (ATR)
- PYPD 0.15
- BUUU 0.00
- MACD
- PYPD 0.02
- BUUU 0.00
- Stochastic Oscillator
- PYPD 67.95
- BUUU 0.00
About PYPD PolyPid Ltd.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.